In Table 1 of the Review “Engineering CAR-T therapies for autoimmune disease and beyond” by E. P. English et al., the sponsors of the clinical trials in the last section, “Engineered cell therapy studies in autoimmune diseases (non-BCMA or -CD19 targets),” were incorrect. The clinical trials and sponsors were originally listed as follows: NCT03605238, NCT05239702, and NCT06361836, Cabaletta Bio; NCT04422912, Tongji Hospital; NCT04561557, Zhejiang University; NCT05451212, Nanjing University School of Medicine; NCT06285279... Читать дальше...